US Bancorp
CPRX

US Bancorp’s Catalyst Pharmaceutical CPRX Stock Holding History

US Bancorp’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$44.3K Sell
1,789
-386
-18% -$9.2K ﹤0.01% 2764
2025
Q4 		$50.8K Sell
2,175
-4,394
-67% -$97.9K ﹤0.01% 2695
2025
Q3 		$129K Buy
6,569
+220
+3% +$4.52K ﹤0.01% 2225
2025
Q2 		$138K Sell
6,349
-979
-13% -$23.1K ﹤0.01% 2256
2025
Q1 		$178K Buy
7,328
+1,105
+18% +$24.9K ﹤0.01% 2074
2024
Q4 		$130K Sell
6,223
-39,150
-86% -$841K ﹤0.01% 2268
2024
Q3 		$902K Sell
45,373
-3,885
-8% -$72K ﹤0.01% 1185
2024
Q2 		$763K Buy
49,258
+773
+2% +$12K ﹤0.01% 1241
2024
Q1 		$773K Sell
48,485
-16,690
-26% -$252K ﹤0.01% 1249
2023
Q4 		$1.1M Buy
65,175
+25,418
+64% +$347K ﹤0.01% 1062
2023
Q3 		$465K Sell
39,757
-5,960
-13% -$79.7K ﹤0.01% 1413
2023
Q2 		$614K Buy
45,717
+8,062
+21% +$116K ﹤0.01% 1287
2023
Q1 		$624K Buy
37,655
+37,543
+33,521% +$619K ﹤0.01% 1290
2022
Q4 		$2.08K Buy
112
+12
+12% +$185 ﹤0.01% 3764
2022
Q3 		$1K Hold
100
– – ﹤0.01% 3929
2022
Q2 		$1K Hold
100
– – ﹤0.01% 3935
2022
Q1 		$1K Buy
+100
New +$707 ﹤0.01% 3925

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

US Bancorp's CPRX Position: Q1 2026 in Review

US Bancorp reduced its Catalyst Pharmaceutical (CPRX) stake by 18% in Q1 2026, selling an estimated $9.2K and leaving 1,789 shares worth $44.3K. The position accounts for ﹤0.01% of the portfolio, ranked #2764.

US Bancorp first reported a position in CPRX in Q1 2022 and has held it in 17 quarters since. The position peaked at $1.1M in Q4 2023. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • US Bancorp held 1,789 shares of Catalyst Pharmaceutical worth $44.3K as of Q1 2026.
  • US Bancorp sold 386 Catalyst Pharmaceutical shares in Q1 2026, an estimated $9.2K.
  • Catalyst Pharmaceutical made up ﹤0.01% of US Bancorp's portfolio in Q1 2026, its #2764 holding.
  • US Bancorp first reported a position in Catalyst Pharmaceutical in Q1 2022 and has held it in 17 quarters since.
  • US Bancorp's Catalyst Pharmaceutical position peaked at $1.1M in Q4 2023.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on US Bancorp's 13F filing for Q1 2026, filed 15 May 2026.